Paris (France), April 5, 2017 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo’s shareholders are invited to attend the Company’s Combined Ordinary and Extraordinary General Meeting which is being held on Wednesday, April 26, 2017 at 10.00 AM CET at Onxeo’s headquarters: 49 Boulevard du Général Martial Valin, 75015 Paris, France.
The official notice of the General Meeting was published in the French Republic’s Bulletin des Annonces Légales Obligatoires (i.e. the “Bulletin of Mandatory Legal Announcements”) on March 22, 2017 and includes the agenda, the draft resolutions, and information on attendance and voting procedures. Under the conditions set out in current legislation, you can find the notice in its full length, together with all other related documents, on Onxeo’s website: http://www.onxeo.com/en/investisseurs/assemblee-generale/
The above-mentioned documents are available to shareholders at the company’s headquarters and on the Company’s website. Shareholders may request to receive the documents by sending their request and postal or email address to Onxeo either by airmail (Direction Financière – 49 boulevard du Général Martial Valin, 75015 Paris, France), fax (+33 1 45 58 08 81), or email (email@example.com)